metformin has been researched along with Rett Syndrome in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Rett Syndrome: An inherited neurological developmental disorder that is associated with X-LINKED INHERITANCE and may be lethal in utero to hemizygous males. The affected female is normal until the age of 6-25 months when progressive loss of voluntary control of hand movements and communication skills; ATAXIA; SEIZURES; autistic behavior; intermittent HYPERVENTILATION; and HYPERAMMONEMIA appear. (From Menkes, Textbook of Child Neurology, 5th ed, p199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin is the most common anti-diabetic drug and a promising therapy for disorders beyond diabetes, including Rett syndrome (RTT), a rare neurologic disease characterized by severe intellectual disability." | 8.31 | Chronic treatment with the anti-diabetic drug metformin rescues impaired brain mitochondrial activity and selectively ameliorates defective cognitive flexibility in a female mouse model of Rett syndrome. ( Cosentino, L; De Filippis, B; Di Crescenzo, L; Di Domenico, F; Lanzillotta, C; Perluigi, M; Pietraforte, D; Prestia, F; Quattrini, MC; Urbinati, C; Vacca, RA; Valenti, D, 2023) |
| "Metformin is the most common anti-diabetic drug and a promising therapy for disorders beyond diabetes, including Rett syndrome (RTT), a rare neurologic disease characterized by severe intellectual disability." | 4.31 | Chronic treatment with the anti-diabetic drug metformin rescues impaired brain mitochondrial activity and selectively ameliorates defective cognitive flexibility in a female mouse model of Rett syndrome. ( Cosentino, L; De Filippis, B; Di Crescenzo, L; Di Domenico, F; Lanzillotta, C; Perluigi, M; Pietraforte, D; Prestia, F; Quattrini, MC; Urbinati, C; Vacca, RA; Valenti, D, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Urbinati, C | 3 |
| Lanzillotta, C | 3 |
| Cosentino, L | 3 |
| Valenti, D | 3 |
| Quattrini, MC | 3 |
| Di Crescenzo, L | 3 |
| Prestia, F | 3 |
| Pietraforte, D | 3 |
| Perluigi, M | 3 |
| Di Domenico, F | 3 |
| Vacca, RA | 3 |
| De Filippis, B | 3 |
1 other study available for metformin and Rett Syndrome